

Name of journal: *World Journal of Hepatology*

ESPS Manuscript NO: 14941

Columns: Original Article

Retrospective Cohort Study

Survival rates according to BCLC sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma

Leandro Armani Scaffaro, Steffan Frosi Stella, Mario Reis Alvares-Da-Silva, Cleber Dario Pinto Kruel

Abstract

AIM: A sub-staging system of BCLC B hepatocellular carcinoma (HCC) has been proposed to facilitate therapeutic decisions. We investigate the survival rates after transarterial embolization (TAE).

Match Overview

1	Internet 35 words crawled on 29-Jul-2014 www.ncbi.nlm.nih.gov	1%
2	CrossCheck 34 words Wang, Jing-Houng, Kwong-Ming Kee, Chih-Yun Lin, Chao-Hung Hung, Chien-Hung Chen, Chuan-Mo Lee, and S	1%
3	CrossCheck 27 words "AASLD Abstracts", Hepatology, 2013.	1%
4	CrossCheck 23 words Bolondi, Luigi, Andrew Burroughs, Jean-François Dufour, Peter Galle, Vincenzo Mazzaferro, Fabio Piscaglia, Jean	1%
5	Internet 22 words crawled on 16-Aug-2009 www.pubmedcentral.nih.gov	1%
6	CrossCheck 21 words Xie, Zhi-Bo, Xiao-Bo Wang, Yu-Chong Peng, Shao-Liang Zhu, Liang Ma, Bang-De Xiang, Wen-Feng Gong, Jie Ch	1%
7	CrossCheck 17 words Weinmann, Arndt, Sandra Koch, Martin Sprinzl, Roman Kloeckner, Henning Schulze-Bergkamen, Christoph Dübe	1%
8	CrossCheck 17 words R S Procianoy. "Massage therapy reduces hospital sta...	1%

网页 图片 新闻 视频 更多 ▾ 搜索工具

找到约 21,400 条结果 (用时 0.62 秒)

Validation and modification of a proposed sub-staging ...

www.ncbi.nlm.nih.gov/pubmed/25088668 - 翻译此页

作者: JH Wang - 2014 - 被引用次数: 1

2014年8月4日 - ... **sub-staging system** for patients with **intermediate hepatocellular carcinoma**. ... sub-stages of **Barcelona Clinic Liver Cancer (BCLC) intermediate** ... 2011, newly diagnosed **intermediate** HCC patients underwent **trans-arterial embolization** ... The 5-year **survival rate** was 21.4%, 13.9%, 7.4% and 7.7% with ...

Validation and modification - Wiley Online Library

onlinelibrary.wiley.com > ... > Vol 30 Issue 2 > Abstract - 翻译此页

2015年1月24日 - **Barcelona Clinic Liver Cancer (BCLC) intermediate** stage; ... **intermediate** HCC patients underwent **transarterial embolization (TAE)** ... For BCLC **intermediate** HCC patients, substages B1–B4 were useful in predicting **survival after TAE**. The proposed **substaging system** for patients with **hepatocellular** ...

Validation and modification of a proposed substaging ...

www.pubfacts.com/.../Validation-and-modification-of-a-propos... ▾ 翻译此页

The 5-year **survival rate** was 21.4%, 13.9%, 7.4%, and 7.7% with median survival time of ... **According** to AFP < or > 200 ng/mL, B1 was classified into B1a and B1b, and B2 into ... **Barcelona Clinic Liver Cancer (BCLC) intermediate** stage ... proposed **substaging system** for patients with **intermediate hepatocellular carcinoma**.

Treatment of intermediate-stage hepatocellular carcinoma



Survival rates according to barcelona clinic liver cancer sub-staging syste



网页

图片

新闻

视频

更多 ▾

搜索工具

找到约 21,400 条结果（用时 0.52 秒）

Validation and modification of a proposed sub-staging ...

www.ncbi.nlm.nih.gov/pubmed/25088668 - 翻译此页

作者: JH Wang - 2014 - 被引用次数: 1

2014年8月4日 - ... sub-staging system for patients with intermediate hepatocellular carcinoma. ... sub-stages of Barcelona Clinic Liver Cancer (BCLC) intermediate ... 2011, newly diagnosed intermediate HCC patients underwent trans-arterial embolization ... The 5-year survival rate was 21.4%, 13.9%, 7.4% and 7.7% with ...

Validation and modification - Wiley Online Library

onlinelibrary.wiley.com > ... > Vol 30 Issue 2 > Abstract - 翻译此页

2015年1月24日 - Barcelona Clinic Liver Cancer (BCLC) intermediate stage; ... intermediate HCC patients underwent transarterial embolization (TAE) ... For BCLC intermediate HCC patients, substages B1–B4 were useful in predicting survival after TAE. The proposed substaging system for patients with hepatocellular ...

Validation and modification of a proposed substaging ...

www.pubfacts.com/.../Validation-and-modification-of-a-propos... - 翻译此页

The 5-year survival rate was 21.4%, 13.9%, 7.4%, and 7.7% with median survival time of ... According to AFP < or > 200 ng/mL, B1 was classified into B1a and B1b, and B2 into ... Barcelona Clinic Liver Cancer (BCLC) intermediate stage ... proposed substaging system for patients with intermediate hepatocellular carcinoma.